Clinical trial
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic…
NCT00102895 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00102895 |
|---|---|
| Title | A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer |
| Official title | An Open-Label, Multi-Center, Phase 2 Study Of Cp 724,714 In Patients With Her2 Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy For Metastatic Disease And Is Previously Untreated With A Her2 Inhibitor |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | CP-724, 714 |
| Enrollment | 25 |
| Start date | Apr 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Feb 4, 2005 |
| Last update posted | Aug 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: